Search
Search Results
##search.searchResults.foundPlural##
-
TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML
1999PDF: 1612HTML: 347 -
HODGKIN LYMPHOMA IN OLDER PATIENTS: AN ORPHAN DISEASE?
2826PDF: 1315HTML: 3552Untitled: 178Untitled: 187Untitled: 166 -
PROLIFERATION AND APOPTOSIS OF B-CELL LYMPHOMA CELLS UNDER TARGETED REGULATION OF FOXO3 BY miR-155 miR-155, FOXO3, B-cell lymphoma, proliferation, apoptosis, clinical characteristics
708PDF: 66HTML: 126 -
THE ROLE OF SLC22A4 IN ACUTE MYELOID LEUKEMIA
411PDF: 220HTML: 71 -
TRANSCRIPTOME ANALYSIS OF BETA-CATENIN-RELATED GENES IN CD34+ HAEMATOPOIETIC STEM AND PROGENITOR CELLS FROM PATIENTS WITH AML Transcriptome analysis of beta-catenin-related genes in AML
977PDF: 1094Suppl. Files: 553HTML: 72 -
RECENT ADVANCES IN THE DEFINITION OF THE MOLECULAR ALTERATIONS OCCURRING IN MULTIPLE MYELOMA MOLECULAR ALTERATIONS OCCURRING IN MM
1130PDF: 1014HTML: 177 -
DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES
1311HTML: 370PDF: 794 -
RARE CYTOGENETIC ABNORMALITIES IN MYELODYSPLASTIC SYNDROMES
3668PDF: 1614HTML: 11502Figures Haase: 178 -
PROGNOSTIC FACTORS IN HODGKIN LYMPHOMA
3211PDF: 1917HTML: 7455 -
INTEREST IN DETERMINING THE CD34+ CD38- PHENOTYPE IN THE DIAGNOSIS AND PROGNOSIS OF ACUTE LEUKEMIA IN ABIDJAN – CÔTE D’IVOIRE
1916PDF: 687HTML: 669Table1: patient's characteristics: 140Table 2: profile of each patient: 165 -
PLASMACELL NEOPLASMS WITH SPREADING IN THE BLOOD AND TISSUES: EXTRAMEDULLARY MYELOMA DISEASE A RARE AGGRESSIVE FORM OF MULTIPLE MYELOMA (First of two parts) Extra Medullary Myeloma
2385HTML: 253PDF: 832 -
EPIDEMIOLOGICAL OVERVIEW OF HODGKIN LYMPHOMA ACROSS THE MEDITERRANEAN BASIN
3451PDF: 1138HTML: 4976Incidence age-standardized rates for HL across the Mediterranean basin: 179 -
NON-SECRETORY MYELOMA: READY FOR A NEW DEFINITION?
3167PDF: 1684HTML: 1071 -
GENETIC PATHWAYS LEADING TO THERAPY-RELATED MYELOID NEOPLASMS
2531PDF: 776HTML: 5177 -
DIAGNOSIS AND SUBCLASSIFICATION OF ACUTE LYMPHOBLASTIC LEUKEMIA
8915PDF: 5966HTML: 87470Fig.1b: 169Fig.1c: 168Fig.2a: 161Fig.2b: 162Fig.4: 172Fig.2c: 164Fig.3: 164Tab.1: 214Tab.2: 192Tab.3: 177Tab.4: 205Fig1a: 164 -
SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH Systemic Mastocytosis
1443PDF: 900HTML: 209 -
PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW (1) Part 1- Epidemiology, pathogenesis, clinicopathologic characteristics, differential diagnosis, prognostic factors and special populations
3454PDF: 2356HTML: 1412 -
SIMILARITIES OF ELDERLY AND THERAPY-RELATED AML
3516PDF: 837HTML: 6696 -
HEPARIN-BINDING PROTEIN AS A DIAGNOSTIC AND PROGNOSTIC MARKER OF INFECTIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS Heparin-binding protein in adult patients
2020PDF: 932HTML: 129Suppl. Files: 497 -
SOLITARY PLASMACYTOMA
3774PDF: 2134HTML: 1202fIGURES 1,2: 194 -
TYROSINE KINASE INHIBITORS AND PREGNANCY
3450PDF: 1582HTML: 2662 -
Guest Editor: Pellegrino Musto REFINING HIGH-RISK MULTIPLE MYELOMA: ADVANCEMENTS IN GENOMIC, CLINICAL, AND PROGNOSTIC CRITERIA Multiple Myeloma High Risk Classificatio
2094PDF: 1535HTML: 248 -
IMMUNOGLOBULIN GENE REPERTOIRE IN CHRONIC LYMPHOCYTIC LEUKEMIA: INSIGHT INTO ANTIGEN SELECTION AND MICROENVIRONMENTAL INTERACTIONS
2989PDF: 844HTML: 7150Kost Fig1: 167Kost Fig 2: 159Kost Fig3: 155Kost Fig 4: 172Kost Fig5: 170Kost fig 6: 156 -
-
MONITORING THE RESPONSE TO TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)
3844PDF: 1447HTML: 9173Untitled: 259Untitled: 167Untitled: 151Untitled: 146Untitled: 163Untitled: 320 -
THERAPY-RELATED MYELOID MALIGNANCIES IN MYELOMA
2410PDF: 761HTML: 1721 -
MANAGEMENT OF ACUTE PROMYELOCYTIC LEUKEMIA IN THE ELDERLY
2709PDF: 1076HTML: 3255 -
“IDENTIFYING HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA: A PATHOGENESIS-ORIENTED APPRAISAL OF PROGNOSTIC AND PREDICTIVE FACTORS IN PATIENTS TREATED WITH CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY.”
3966PDF: 1014HTML: 3558Untitled: 165Cneo. Fig.1: 100Untitled: 89Untitled: 113Untitled: 116 -
TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS
2745PDF: 981HTML: 5498 -







